They further investigated the protective effect of these induced OVA-specific CD8+ T cells against OVA-expressing melanoma cells by immunizing the mice using the same aforementioned process and then challenging the mice with OVA-expressing melanoma cells on day 13 after the prime vaccination. Here, CD8A is linked to melanoma.